Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Similar articles for PubMed (Select 23688389)


Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels.

Meng K, Tian W, Zhou M, Chen H, Deng Y.

World J Surg Oncol. 2013 May 20;11:101. doi: 10.1186/1477-7819-11-101.


Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.

Guerrero A, Gavilá J, Folkerd E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A.

Ann Oncol. 2013 Mar;24(3):674-9. doi: 10.1093/annonc/mds464. Epub 2012 Oct 28.


[Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].

Li HP, Ma LW, Zhang SL, Jia TZ, Deng HJ, Zhang ZH, Liang L, Wang MP, Xiao Y, Cao BS, Chen S, Wang YF.

Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):848-51. Chinese.


Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.

Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, Park JY, Park KO, Yoon DH, Kim SB.

Cancer Chemother Pharmacol. 2013 Sep;72(3):565-75. doi: 10.1007/s00280-013-2227-5. Epub 2013 Jul 11.


Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.

Dieudonné AS, Vandenberghe J, Geerts I, Billen J, Paridaens R, Wildiers H, Neven P.

Menopause. 2011 Jul;18(7):821-4. doi: 10.1097/gme.0b013e318204af88.


Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.

Torino F, Barnabei A, De Vecchis L, Appetecchia M, Strigari L, Corsello SM.

Endocr Relat Cancer. 2012 Apr 10;19(2):R21-33. doi: 10.1530/ERC-11-0199. Print 2012 Apr. Review.


Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.


Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A.

Breast Cancer Res Treat. 2010 Feb;120(1):245-51. doi: 10.1007/s10549-009-0426-x. Epub 2009 Jul 3.


Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F.

Ann Oncol. 2004 Jul;15(7):1065-71.


Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer.

Torino F, Barnabei A, De Vecchis L, Sini V, Schittulli F, Marchetti P, Corsello SM.

Crit Rev Oncol Hematol. 2014 Jan;89(1):27-42. doi: 10.1016/j.critrevonc.2013.07.007. Epub 2013 Aug 13. Review.


Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA.

Breast Cancer Res Treat. 2009 Jan;113(2):315-20. doi: 10.1007/s10549-008-9937-0. Epub 2008 Feb 27.


Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M.

JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991.


Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.

Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, Kim SW, Jung S, Ro J.

Ann Oncol. 2012 Sep;23(9):2283-9. doi: 10.1093/annonc/mds006. Epub 2012 Feb 29.


Tamoxifen and ovarian function.

Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, Van Maanen A, Piette P, Machiels JP.

PLoS One. 2013 Jun 28;8(6):e66616. doi: 10.1371/journal.pone.0066616. Print 2013.


The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R.

Am J Clin Oncol. 2007 Apr;30(2):126-32.


Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study.

Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ.

Cancer. 2010 Jul 1;116(13):3102-11. doi: 10.1002/cncr.25106.


Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.

Davis AL, Klitus M, Mintzer DM.

Clin Breast Cancer. 2005 Dec;6(5):421-4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk